Mass spectrometric methods of determining levels of glycated CD59

Summary CD59 is a protein that exists in both glycated and non-glycated forms. An elevated ratio of glycated to non-glycated CD59 has been found to be an early (i.e., pre-symptomatic) prognostic marker for the onset of diabetes, as well as for its devastating vascular complications. In addition to its utility as an early diagnostic tool, measurement of CD59 glycation provides a more robust and convenient means by which to monitor glycemic control in diabetes patients than is offered by blood glucose testing, as it is unaffected by transient events (e.g., individual meals or snacks) and need only be performed weekly or monthly, rather than numerous times a day, to provide information about long-term patient wellbeing. Quantitation of glycated CD59 also is useful as a personalized medicine tool, i.e., to help select the most appropriate course of treatment for a given patient.

Applications Diagnosis and monitoring of patients with diabetes and those at risk of developing the disease. For Further Information Please Contact the Director of Business Development Alex Szidon Email: alex_szidon@harvard.edu Telephone: (617) 495-3067

Inventor(s): Halperin, Jose A.

Type of Offer: Licensing



Next Patent »
« More Diagnostic Patents

Share on      


CrowdSell Your Patent